FLT Stock Recent News

Advancing Aerial Intelligence with proprietary software - AIRS (Aerial Intelligence Reporting System) TORONTO, ON / ACCESS Newswire / January 30, 2025 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A2JEQU) ("Volatus" or "the Company") is pleased to announce that it has surpassed 75,000 flight hours conducting pipeline integrity monitoring. This milestone reinforces the company's leadership in aerial inspection services and underscores its commitment to supporting critical energy infrastructure with advanced monitoring solutions.

TORONTO, ON / ACCESSWIRE / January 6, 2025 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y) ("Volatus" or "the Company") is pleased to announce the renewal and expansion of one of its major U.S.-based power utility inspection programs for 2025. This milestone reflects the company's growing presence in the energy utilities sector and its ability to deliver innovative aerial solutions that address the evolving needs of its customers.

TORONTO, ON / ACCESSWIRE / December 30, 2024 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or the "Company") has, in line with TSX Venture Exchange (TSXV) guidelines and Volatus Aerospace's commitment to long-term growth, successfully converted $145,545 in preferred shares into common shares. This move, part of the original terms for the acquisition of UAViation Aerial Solutions Ltd in 2020, simplifies the Company's capital structure and enhances shareholder value.

REDWOOD CITY, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company's investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System.

REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Monday, December 9, 2024 at 4:30 pm EST to present data from COVALENT-103, the company's Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION™ System, in adult patients with relapsed or refractory acute leukemia.

TORONTO, ON / ACCESSWIRE / October 1, 2024 / Volatus Aerospace Inc. (TSXV:FLT)(OTCQX:TAKOF)(Frankfurt:A3DP5Y/ABBA.F) has been ranked second on the 2024 Canada's Top Growing Companies list, published by The Globe and Mail's Report on Business on September 27th, 2024. The ranking highlights 416 of Canada's fastest-growing businesses, evaluated based on three-year revenue growth.

MADRID and CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents preliminary data from its ongoing Phase Ib FRIDA study investigating iadademstat in combination with gilteritinib in relapsed/refractory acute myeloid leukemia (AML) patients harboring a FMS-like tyrosine kinase mutation (FLT3 mut+) at the European Hematology Association (EHA) 2024 congress, being held in Madrid (Spain) on June 13–16. Dr. Amir Fathi, from the Massachusetts General Hospital and Principal Investigator of the study, will present a poster communication entitled “Preliminary results of the FRIDA study: iadademstat and gilteritinib in FLT3-mutated R/R AML”.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

FLEETCOR is an overlooked quality company that is currently undervalued. We have used three different valuation methods, and FLT appears undervalued in all three. Despite its high revenue and earnings growth, FLEETCOR has significantly underperformed the S&P 500 in the past five years.